AYTU AYTU BIOPHARMA, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1385818 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.1%
TTM net income YoY-53.8%
TTM EPS YoY-55.0%
Revenue 3-yr CAGR-15.7%
Net income 3-yr CAGR—
Margins
Gross margin63.3%
Operating margin-18.4%
Net margin-34.3%
FCF margin—
EBITDA margin-14.2%
Returns
ROE-73.4%
ROA-17.9%
ROIC (approx.)-87.4%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets68.2%
Debt / equity0.33x
Current ratio1.07x
Interest coverage-6.01x
Cash quality & payout
Operating cash flow / net income-0.18x
Accruals ratio-21.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $57.57M | $66.38M |
| Cost of revenue | $20.75M | $20.55M |
| Gross profit | $36.82M | $45.83M |
| R&D expense | $0 | $1.33M |
| SG&A expense | $19.27M | $17.38M |
| Operating income | -$8.31M | -$7.83M |
| Interest expense | $1.90M | $3.70M |
| Pretax income | -$14.23M | -$13.74M |
| Income tax | $21,000 | $437,000 |
| Net income | -$14.25M | -$13.56M |
| EBITDA | -$4.38M | -$2.45M |
| EPS (basic) | -1.16 | -2.16 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $26.31M | $30.95M |
| Receivables | $22.78M | $31.16M |
| Inventory | $6.86M | $11.43M |
| Current assets | $61.76M | $79.18M |
| PP&E, net | $385,000 | $532,000 |
| Intangibles | $41.40M | $42.20M |
| Total assets | $105.01M | $124.18M |
| Current liabilities | $54.66M | $63.06M |
| Short-term debt | $1.86M | $1.86M |
| Long-term debt | $9.10M | $10.89M |
| Total debt | $10.96M | $12.75M |
| Total liabilities | $69.73M | $105.21M |
| Shareholders' equity | $35.27M | $18.97M |
| Net debt | -$15.35M | -$18.20M |
| Shares outstanding | 10.73M | 8.98M |
| Cash flow statement | ||
| Operating cash flow | $3.28M | -$1.94M |
| Capital expenditure | $29,000 | $228,000 |
| Free cash flow | $3.25M | -$2.17M |
| Investing cash flow | -$29,000 | -$2.56M |
| Financing cash flow | -$7.90M | $15.44M |
| Depreciation & amortization | $3.93M | $5.38M |
| Stock-based compensation | $691,000 | $576,000 |
Free plan shows the latest 2 periods; Pro shows all 21 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.